ClinicalTrials.gg
TerminatedNCT03370302Updated Feb 8, 2023Results posted

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult East Asian Participants With Advanced Nonhematological Malignancies

A Phase 1 interventional study of TAK-228 in Advanced Nonhematological Neoplasms, sponsored by Calithera Biosciences, Inc. Terminated at 4 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-08.

Sponsored by Calithera Biosciences, Inc · Phase 1, Interventional, and Other

Why this study was terminated
More favorable safety profile was observed in QD schedule, therefore further enrollment in QW schedule was terminated.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety and tolerability, recommended phase 2 dose (RP2D), and to characterize PK of TAK-228 administered once daily or once weekly to East Asian participants with advanced nonhematological malignancies.

Read the detailed description

The drug being tested in this study is called TAK-228. TAK-228 is being tested to treat East Asian participants with advanced nonhematological malignancies for whom standard anticancer treatment is not available or is no longer effective. This study will assess the safety, tolerability, PK and will determine the RP2Ds of TAK-228.

The study will enroll approximately 46 participants, including at least 6 Japanese participants at RP2D dose level. Participants will be assigned to one of the following treatment arms:

  • TAK-228 Once Daily
  • TAK-228 Once Weekly

This multi-center trial will be conducted in South Korea, Taiwan, and Japan. The overall time to participate in this study is up to 12 months, unless in the opinion of the investigator and sponsor the participant would derive benefit from continued therapy beyond 12 months. Participants will be followed for 30 days after last dose of study drug for a follow-up assessment.

02

Conditions studied

  • Advanced Nonhematological Neoplasms

Keywords

  • Drug therapy
03

In context

Lead sponsor

Calithera Biosciences, Inc is the lead sponsor of 29 studies on the registry; none are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 10 (59%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. With advanced nonhematologic , with the exception of primary brain tumor, and have failed or are not eligible for standard of care therapy. History of may be allowed if all of the following criteria are met:

    • Brain metastases have been treated.
    • There is no evidence of progression or hemorrhage after treatment.
    • has been discontinued for >=4 weeks before the first dose of study drug.
    • There is no ongoing requirement for steroids or anti-epileptic drugs.
  2. Received not more than 4 prior lines of systemic cytotoxic chemotherapy for advanced or disease.
  3. (ECOG) performance status 0 to 1.
  4. Screening clinical laboratory values as specified below:

    • Bone marrow reserve consistent with (ANC) >=2000 per cubic millimeter (/mm\^3), count >=125,000/mm\^3, and >=10 gram per deciliter (g/dL) without transfusion in the last 4 weeks.

Note: Prophylactic transfusions of blood products or any prophylactic use of hematopoietic growth factors (such as erythropoietin, thrombopoietin, granulocyte colony stimulating factor [G-CSF], and granulocyte macrophage colony stimulating factor [GM-CSF]) is not permitted during the screening period.

  • Hepatic: Total less than or equal to (\<=) 1.5* (ULN), (ALT)/aspartate aminotransferase (AST) \<=2.5*ULN (\<=5*ULN if their elevation can be reasonably ascribed to the presence of hepatocellular carcinoma, biliary tract cancer, or metastatic disease in liver).
  • Adequate renal function, defined as meeting any 1 of the following criteria:

    1. Serum creatinine \<1.5*ULN.
    2. based on the Cockcroft-Gault estimate >=40 milliliter per minute (mL/min).
    3. Creatinine clearance based on urine collection (12- or 24-hour) >=40 mL/min.
    4. Metabolic: Glycosylated hemoglobin ( [HbA1c]) \<=7%, fasting serum glucose \<=130 milligram per deciliter (mg/dL), and fasting triglycerides \<=300 mg/dL.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of primary brain tumor.
  2. Untreated or history of or spinal cord compression.
  3. Failed to recover from the reversible effects of prior anticancer therapies with the exception of alopecia, and after-effects associated with prior tyrosine kinase inhibitor therapy, such as hair depigmentation, hypothyroidism, and/or splinter hemorrhage.
  4. Initiation of hematopoietic growth factors within 1 week before the first dose of study drug.
  5. Manifestations of malabsorption caused by prior gastrointestinal surgery, gastrointestinal disease, or for some other reason that may alter the absorption of TAK-228. In addition, participants with enteric stomata are also excluded.
  6. Poorly controlled diabetes mellitus defined as (HbA1c) greater than (>) 7%; participants with a history of transient glucose intolerance caused by administration are allowed if all other eligibility criteria are met.
  7. Known infection.
  8. Known surface antigen (HBsAg) positive, or known or suspected active virus (HCV) infection. Note: Participants who have isolated positive hepatitis B core antibody (HBcAb) and/or hepatitis B surface antibody (HBsAb) (that is, in the setting of negative HBsAg) may be enrolled but must have an undetectable hepatitis B virus (HBV) viral load. Participants who have positive hepatitis C virus antibody (HCVAb) may be enrolled but must have an undetectable HCV viral load.
  9. Significant active cardiovascular or pulmonary disease before the first dose of study drug, including:

    • Uncontrolled hypertension (that is, systolic blood pressure >180 millimeter of mercury [mmHg]; diastolic blood pressure >95 mmHg).
    • Pulmonary hypertension.
    • Uncontrolled asthma or oxygen saturation less than (\<) 90% by pulse oximetry on room air.
    • Significant valvular disease; severe regurgitation or stenosis by imaging independent of symptom control with medical intervention; or history of valve replacement.
    • Medically significant (symptomatic) bradycardia.
    • History of arrhythmia requiring an implantable cardiac defibrillator.
    • Baseline prolongation of the rate interval (QTc) (example, repeated demonstration of QTc interval >480 millisecond [ms], or history of congenital long QT syndrome, or torsades de pointes).
  10. Diagnosed or treated for another within 2 years before the first dose or previously diagnosed with another malignancy and have any evidence of residual disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    TAK-228 Once Daily

    TAK-228, milled capsule, orally, once daily, on an empty stomach in a 28-day treatment cycle for up to 12 months or until disease progression or unacceptable toxicity or withdrawal of consent with a starting dose of 2 milligram (mg) in Cohort 1. Dose escalation will follow a standard 3+3 schema. If 2 mg, once daily, is safe and tolerable, then the dose will be escalated to 4 mg, once daily, until RP2D is determined.

    Drug: TAK-228

  • Experimental
    TAK-228 Once Weekly

    TAK-228, milled capsule, orally, once weekly, on an empty stomach in Cycle 1 of a 28-day treatment cycle and following a light meal from Cycle 2 for up to 12 months or until disease progression or unacceptable toxicity or withdrawal of consent with a starting dose of 20 mg in Cohort 1. Dose escalation will follow a standard 3+3 schema. If 20 mg, once weekly, is safe and tolerable, then the dose will be escalated to 30 mg, once weekly, until RP2D is determined.

    Drug: TAK-228

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    Time frame: Baseline up to 30 days after the last dose of study drug (up to Cycle 12 Day 58) (Cycle length= 28 days)

  2. Number of Participants With Grade 3 or Higher TEAEs

    Adverse event (AE) Grades were evaluated as per National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE), version 4.03. Grade 1 scaled as Mild; Grade 2 scaled as Moderate; Grade 3 scaled as severe or medically significant but not immediately life-threatening; Grade 4 scaled as life-threatening consequences; and Grade 5 scaled as death related to AE.

    Time frame: Baseline up to 30 days after the last dose of study drug (up to Cycle 12 Day 58) (Cycle length= 28 days)

  3. Number of Participants With Serious TEAEs

    Time frame: Baseline up to 30 days after the last dose of study drug (up to Cycle 12 Day 58) (Cycle length= 28 days)

  4. Dose Escalation Phase: Number of Participants With Dose-limiting Toxicities (DLTs) During Cycle 1

    Toxicity was evaluated according to NCI CTCAE version 4.03. DLT was defined as any of the following occurred events within the first 28 days of the administration of TAK-228 that were considered by investigator to be possibly related to therapy: Grade \>=3 nonhematologic toxicity except for inadequately treated Grade 3 nausea and/or vomiting and diarrhea, Grade 3 hyperglycemia lasting \<=14 days, Grade 3 rash lasting \<=3 days; Grade 3 thrombocytopenia with hemorrhage or requiring platelet transfusion; Grade 3 anemia requiring blood transfusion; Grade 4 neutropenia lasting \>7 days; Grade \>=3 neutropenia of any duration with fever \>=38.5 degree celsius and/or systemic infection; Any other \>=Grade 4 hematologic toxicity; Inability to administer at least 75 percent (%) of planned doses of TAK-228 within Cycle 1 due to treatment-related toxicity and any clinically significant occurrence that the investigators and sponsor agreed would place participants at an undue safety risk.

    Time frame: Baseline up to Day 28 in Cycle 1 (Cycle length= 28 days)

  5. Number of Participants With TEAEs Leading to Study Drug Discontinuation

    Time frame: Baseline up to 30 days after the last dose of study drug (up to Cycle 12 Day 58) (Cycle length= 28 days)

  6. Cmax: Maximum Observed Plasma Concentration for TAK-228 on Cycle 1 Day 1

    Time frame: Cycle 1 Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose (Cycle length= 28 days)

  7. Cmax: Maximum Observed Plasma Concentration for TAK-228 on Cycle 1 Day 15

    Time frame: Cycle 1 Day 15 pre-dose and at multiple time points (up to 24 hours) post-dose (Cycle length= 28 days)

  8. Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-228 on Cycle 1 Day 1

    Time frame: Cycle 1 Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose (Cycle length= 28 days)

  9. Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-228 on Cycle 1 Day 15

    Time frame: Cycle 1 Day 15 pre-dose and at multiple time points (up to 24 hours) post-dose (Cycle length= 28 days)

  10. Daily Dosing Arms, AUC24: Area Under the Plasma Concentration-time Curve From 0 to 24 Hours for TAK-228 on Cycle 1 Day 1

    Time frame: Cycle 1 Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose (Cycle length= 28 days)

  11. Daily Dosing Arms, AUC24: Area Under the Plasma Concentration-time Curve From 0 to 24 Hours for TAK-228 on Cycle 1 Day 15

    Time frame: Cycle 1 Day 15 pre-dose and at multiple time points (up to 24 hours) post-dose (Cycle length= 28 days)

  12. Weekly Dosing Arms, AUC168: Area Under the Concentration-time Curve From 0 to 168 Hours for TAK-228 on Cycle 1 Day 1

    Time frame: Cycle 1 Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose (Cycle length= 28 days)

  13. Weekly Dosing Arms, AUC168: Area Under the Concentration-time Curve From 0 to 168 Hours for TAK-228 on Cycle 1 Day 15

    Time frame: Cycle 1 Day 15 pre-dose and at multiple time points (up to 168 hours) post-dose (Cycle length= 28 days)

  14. AUClast: Area Under the Plasma Concentration-time Curve From 0 to Time of Last Measurable Concentration for TAK-228 on Cycle 1 Day 1

    Time frame: Cycle 1 Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose (Cycle length= 28 days)

  15. AUClast: Area Under the Plasma Concentration-time Curve From 0 to Time of Last Measurable Concentration for TAK-228 on Cycle 1 Day 15

    Time frame: Cycle 1 Day 15 pre-dose and at multiple time points (up to 168 hours) post-dose (Cycle length= 28 days)

  16. AUC∞: Area Under the Plasma Concentration-time Curve From 0 to Infinity for TAK-228 on Cycle 1 Day 1

    Time frame: Cycle 1 Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose (Cycle length= 28 days)

Secondary outcomes

  1. Clinical Benefit Rate (CBR)

    The CBR was defined as the percentage of participants with a best overall response (BOR) of complete response (CR), partial response (PR), or stable disease (SD). BOR was defined as the best response recorded after the first dose of study drug until subsequent therapy. As per Response Evaluation Criteria Solid Tumors (RECIST) version 1.1 guidelines, CR was defined as disappearance of all target lesions and non-target lesions, and normalization of tumor marker level. PR was defined as \>= 30% decrease in the sum of the longest diameter (LD) of target lesions, no progression in non-target lesion, and no new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression (PD). PD was defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.

    Time frame: Baseline Up to 1 Year 7 Months

07

Results

Posted Sep 9, 2020

Participant flow

Participants took part in the study at 4 investigative sites in Japan, South Korea and Taiwan from 17 January 2018 to 28 August 2019.

Dose Escalation Phase
Participant flow — Dose Escalation Phase
MilestoneDose Escalation, Daily Dosing Arm: TAK-228 2 mgDose Escalation, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Daily Dosing Arm: TAK-228 4 mgDose Expansion, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Weekly Dosing Arm: TAK-228 20 mgDose Escalation, Weekly Dosing Arm: TAK-228 30 mg
Started367033
Completed000000
Not completed367033
Withdrew: Other011000
Withdrew: Withdrawal by subject012002
Withdrew: Adverse event102000
Withdrew: Progressive disease242031
Dose Expansion Phase
Participant flow — Dose Expansion Phase
MilestoneDose Escalation, Daily Dosing Arm: TAK-228 2 mgDose Escalation, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Daily Dosing Arm: TAK-228 4 mgDose Expansion, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Weekly Dosing Arm: TAK-228 20 mgDose Escalation, Weekly Dosing Arm: TAK-228 30 mg
Started000600
Completed000000
Not completed000600
Withdrew: Progressive disease000600

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)
Time frame:
Baseline up to 30 days after the last dose of study drug (up to Cycle 12 Day 58) (Cycle length= 28 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsDose Escalation, Daily Dosing Arm: TAK-228 2 mgDose Escalation, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Daily Dosing Arm: TAK-228 4 mgDose Expansion, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Weekly Dosing Arm: TAK-228 20 mgDose Escalation, Weekly Dosing Arm: TAK-228 30 mg
Number of Participants With Treatment Emergent Adverse Events (TEAEs)367633
PrimaryNumber of Participants With Grade 3 or Higher TEAEs

Adverse event (AE) Grades were evaluated as per National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE), version 4.03. Grade 1 scaled as Mild; Grade 2 scaled as Moderate; Grade 3 scaled as severe or medically significant but not immediately life-threatening; Grade 4 scaled as life-threatening consequences; and Grade 5 scaled as death related to AE.

Time frame:
Baseline up to 30 days after the last dose of study drug (up to Cycle 12 Day 58) (Cycle length= 28 days)
Reported as:
Count of participants · Participants
Number of Participants With Grade 3 or Higher TEAEs
ParticipantsDose Escalation, Daily Dosing Arm: TAK-228 2 mgDose Escalation, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Daily Dosing Arm: TAK-228 4 mgDose Expansion, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Weekly Dosing Arm: TAK-228 20 mgDose Escalation, Weekly Dosing Arm: TAK-228 30 mg
Number of Participants With Grade 3 or Higher TEAEs126531
PrimaryNumber of Participants With Serious TEAEs
Time frame:
Baseline up to 30 days after the last dose of study drug (up to Cycle 12 Day 58) (Cycle length= 28 days)
Reported as:
Count of participants · Participants
Number of Participants With Serious TEAEs
ParticipantsDose Escalation, Daily Dosing Arm: TAK-228 2 mgDose Escalation, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Daily Dosing Arm: TAK-228 4 mgDose Expansion, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Weekly Dosing Arm: TAK-228 20 mgDose Escalation, Weekly Dosing Arm: TAK-228 30 mg
Number of Participants With Serious TEAEs023121
PrimaryDose Escalation Phase: Number of Participants With Dose-limiting Toxicities (DLTs) During Cycle 1

Toxicity was evaluated according to NCI CTCAE version 4.03. DLT was defined as any of the following occurred events within the first 28 days of the administration of TAK-228 that were considered by investigator to be possibly related to therapy: Grade \>=3 nonhematologic toxicity except for inadequately treated Grade 3 nausea and/or vomiting and diarrhea, Grade 3 hyperglycemia lasting \<=14 days, Grade 3 rash lasting \<=3 days; Grade 3 thrombocytopenia with hemorrhage or requiring platelet transfusion; Grade 3 anemia requiring blood transfusion; Grade 4 neutropenia lasting \>7 days; Grade \>=3 neutropenia of any duration with fever \>=38.5 degree celsius and/or systemic infection; Any other \>=Grade 4 hematologic toxicity; Inability to administer at least 75 percent (%) of planned doses of TAK-228 within Cycle 1 due to treatment-related toxicity and any clinically significant occurrence that the investigators and sponsor agreed would place participants at an undue safety risk.

Time frame:
Baseline up to Day 28 in Cycle 1 (Cycle length= 28 days)
Reported as:
Count of participants · Participants
Dose Escalation Phase: Number of Participants With Dose-limiting Toxicities (DLTs) During Cycle 1
ParticipantsDose Escalation, Daily Dosing Arm: TAK-228 2 mgDose Escalation, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Daily Dosing Arm: TAK-228 4 mgDose Escalation, Weekly Dosing Arm: TAK-228 20 mgDose Escalation, Weekly Dosing Arm: TAK-228 30 mg
Dose Escalation Phase: Number of Participants With Dose-limiting Toxicities (DLTs) During Cycle 100300
PrimaryNumber of Participants With TEAEs Leading to Study Drug Discontinuation
Time frame:
Baseline up to 30 days after the last dose of study drug (up to Cycle 12 Day 58) (Cycle length= 28 days)
Reported as:
Count of participants · Participants
Number of Participants With TEAEs Leading to Study Drug Discontinuation
ParticipantsDose Escalation, Daily Dosing Arm: TAK-228 2 mgDose Escalation, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Daily Dosing Arm: TAK-228 4 mgDose Expansion, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Weekly Dosing Arm: TAK-228 20 mgDose Escalation, Weekly Dosing Arm: TAK-228 30 mg
Number of Participants With TEAEs Leading to Study Drug Discontinuation102001
PrimaryCmax: Maximum Observed Plasma Concentration for TAK-228 on Cycle 1 Day 1
Time frame:
Cycle 1 Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose (Cycle length= 28 days)
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Cmax: Maximum Observed Plasma Concentration for TAK-228 on Cycle 1 Day 1
nanogram per milliliter (ng/mL)Dose Escalation, Daily Dosing Arm: TAK-228 2 mgDose Escalation, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Daily Dosing Arm: TAK-228 4 mgDose Expansion, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Weekly Dosing Arm: TAK-228 20 mgDose Escalation, Weekly Dosing Arm: TAK-228 30 mg
Cmax: Maximum Observed Plasma Concentration for TAK-228 on Cycle 1 Day 123.83 ± 9.641.35 ± 29.655.25 ± 26.241.78 ± 23.7252.29 ± 75.2268.61 ± 57.8
PrimaryCmax: Maximum Observed Plasma Concentration for TAK-228 on Cycle 1 Day 15
Time frame:
Cycle 1 Day 15 pre-dose and at multiple time points (up to 24 hours) post-dose (Cycle length= 28 days)
Reported as:
Geometric mean · ng/mL
Cmax: Maximum Observed Plasma Concentration for TAK-228 on Cycle 1 Day 15
ng/mLDose Escalation, Daily Dosing Arm: TAK-228 2 mgDose Escalation, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Daily Dosing Arm: TAK-228 4 mgDose Expansion, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Weekly Dosing Arm: TAK-228 20 mgDose Escalation, Weekly Dosing Arm: TAK-228 30 mg
Cmax: Maximum Observed Plasma Concentration for TAK-228 on Cycle 1 Day 1531.07 ± 48.646.85 ± 31.652.68 ± 47.245.02 ± 44.5182.75 ± 70.5364.58 ± 37.1
PrimaryTmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-228 on Cycle 1 Day 1
Time frame:
Cycle 1 Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose (Cycle length= 28 days)
Reported as:
Median · hours
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-228 on Cycle 1 Day 1
hoursDose Escalation, Daily Dosing Arm: TAK-228 2 mgDose Escalation, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Daily Dosing Arm: TAK-228 4 mgDose Expansion, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Weekly Dosing Arm: TAK-228 20 mgDose Escalation, Weekly Dosing Arm: TAK-228 30 mg
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-228 on Cycle 1 Day 10.870 (0.50 to 2.03)0.990 (0.42 to 1.77)1.000 (0.50 to 2.00)0.500 (0.40 to 1.02)0.470 (0.40 to 2.08)1.970 (1.00 to 2.02)
PrimaryTmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-228 on Cycle 1 Day 15
Time frame:
Cycle 1 Day 15 pre-dose and at multiple time points (up to 24 hours) post-dose (Cycle length= 28 days)
Reported as:
Median · hours
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-228 on Cycle 1 Day 15
hoursDose Escalation, Daily Dosing Arm: TAK-228 2 mgDose Escalation, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Daily Dosing Arm: TAK-228 4 mgDose Expansion, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Weekly Dosing Arm: TAK-228 20 mgDose Escalation, Weekly Dosing Arm: TAK-228 30 mg
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-228 on Cycle 1 Day 151.000 (0.50 to 2.08)0.965 (0.52 to 1.98)1.500 (0.92 to 3.00)1.000 (0.85 to 2.08)2.630 (1.97 to 4.10)2.000 (0.50 to 2.00)
PrimaryDaily Dosing Arms, AUC24: Area Under the Plasma Concentration-time Curve From 0 to 24 Hours for TAK-228 on Cycle 1 Day 1
Time frame:
Cycle 1 Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose (Cycle length= 28 days)
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
Daily Dosing Arms, AUC24: Area Under the Plasma Concentration-time Curve From 0 to 24 Hours for TAK-228 on Cycle 1 Day 1
nanogram*hour per milliliter (ng*hr/mL)Dose Escalation, Daily Dosing Arm: TAK-228 2 mgDose Escalation, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Daily Dosing Arm: TAK-228 4 mgDose Expansion, Daily Dosing Arm: TAK-228 3 mg
Daily Dosing Arms, AUC24: Area Under the Plasma Concentration-time Curve From 0 to 24 Hours for TAK-228 on Cycle 1 Day 1131.0311 ± 43.269192.2467 ± 32.263295.5497 ± 41.724177.9464 ± 38.813
PrimaryDaily Dosing Arms, AUC24: Area Under the Plasma Concentration-time Curve From 0 to 24 Hours for TAK-228 on Cycle 1 Day 15
Time frame:
Cycle 1 Day 15 pre-dose and at multiple time points (up to 24 hours) post-dose (Cycle length= 28 days)
Reported as:
Geometric mean · ng*hr/mL
Daily Dosing Arms, AUC24: Area Under the Plasma Concentration-time Curve From 0 to 24 Hours for TAK-228 on Cycle 1 Day 15
ng*hr/mLDose Escalation, Daily Dosing Arm: TAK-228 2 mgDose Escalation, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Daily Dosing Arm: TAK-228 4 mgDose Expansion, Daily Dosing Arm: TAK-228 3 mg
Daily Dosing Arms, AUC24: Area Under the Plasma Concentration-time Curve From 0 to 24 Hours for TAK-228 on Cycle 1 Day 15221.0132 ± 47.912250.4458 ± 29.806341.1219 ± 44.219278.5369 ± 74.527
PrimaryWeekly Dosing Arms, AUC168: Area Under the Concentration-time Curve From 0 to 168 Hours for TAK-228 on Cycle 1 Day 1
Time frame:
Cycle 1 Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose (Cycle length= 28 days)
Reported as:
Geometric mean · ng*hr/mL
Weekly Dosing Arms, AUC168: Area Under the Concentration-time Curve From 0 to 168 Hours for TAK-228 on Cycle 1 Day 1
ng*hr/mLDose Escalation, Weekly Dosing Arm: TAK-228 20 mgDose Escalation, Weekly Dosing Arm: TAK-228 30 mg
Weekly Dosing Arms, AUC168: Area Under the Concentration-time Curve From 0 to 168 Hours for TAK-228 on Cycle 1 Day 11636.7580 ± 49.9072010.5661 ± 53.631
PrimaryWeekly Dosing Arms, AUC168: Area Under the Concentration-time Curve From 0 to 168 Hours for TAK-228 on Cycle 1 Day 15
Time frame:
Cycle 1 Day 15 pre-dose and at multiple time points (up to 168 hours) post-dose (Cycle length= 28 days)
Reported as:
Geometric mean · ng*hr/mL
Weekly Dosing Arms, AUC168: Area Under the Concentration-time Curve From 0 to 168 Hours for TAK-228 on Cycle 1 Day 15
ng*hr/mLDose Escalation, Weekly Dosing Arm: TAK-228 20 mgDose Escalation, Weekly Dosing Arm: TAK-228 30 mg
Weekly Dosing Arms, AUC168: Area Under the Concentration-time Curve From 0 to 168 Hours for TAK-228 on Cycle 1 Day 151860.7705 ± 42.9892958.0487 ± 47.602
PrimaryAUClast: Area Under the Plasma Concentration-time Curve From 0 to Time of Last Measurable Concentration for TAK-228 on Cycle 1 Day 1
Time frame:
Cycle 1 Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose (Cycle length= 28 days)
Reported as:
Geometric mean · ng*hr/mL
AUClast: Area Under the Plasma Concentration-time Curve From 0 to Time of Last Measurable Concentration for TAK-228 on Cycle 1 Day 1
ng*hr/mLDose Escalation, Daily Dosing Arm: TAK-228 2 mgDose Escalation, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Daily Dosing Arm: TAK-228 4 mgDose Expansion, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Weekly Dosing Arm: TAK-228 20 mgDose Escalation, Weekly Dosing Arm: TAK-228 30 mg
AUClast: Area Under the Plasma Concentration-time Curve From 0 to Time of Last Measurable Concentration for TAK-228 on Cycle 1 Day 1123.6468 ± 54.137175.6252 ± 45.734306.5602 ± 39.279173.5642 ± 44.3391471.9032 ± 45.6921839.6167 ± 52.905
PrimaryAUClast: Area Under the Plasma Concentration-time Curve From 0 to Time of Last Measurable Concentration for TAK-228 on Cycle 1 Day 15
Time frame:
Cycle 1 Day 15 pre-dose and at multiple time points (up to 168 hours) post-dose (Cycle length= 28 days)
Reported as:
Geometric mean · ng*hr/mL
AUClast: Area Under the Plasma Concentration-time Curve From 0 to Time of Last Measurable Concentration for TAK-228 on Cycle 1 Day 15
ng*hr/mLDose Escalation, Daily Dosing Arm: TAK-228 2 mgDose Escalation, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Daily Dosing Arm: TAK-228 4 mgDose Expansion, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Weekly Dosing Arm: TAK-228 20 mgDose Escalation, Weekly Dosing Arm: TAK-228 30 mg
AUClast: Area Under the Plasma Concentration-time Curve From 0 to Time of Last Measurable Concentration for TAK-228 on Cycle 1 Day 15220.1116 ± 47.966240.1012 ± 38.261322.9544 ± 51.178276.9650 ± 74.3141590.2451 ± 38.7702690.2403 ± 45.633
PrimaryAUC∞: Area Under the Plasma Concentration-time Curve From 0 to Infinity for TAK-228 on Cycle 1 Day 1
Time frame:
Cycle 1 Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose (Cycle length= 28 days)
Reported as:
Geometric mean · ng*hr/mL
AUC∞: Area Under the Plasma Concentration-time Curve From 0 to Infinity for TAK-228 on Cycle 1 Day 1
ng*hr/mLDose Escalation, Daily Dosing Arm: TAK-228 2 mgDose Escalation, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Daily Dosing Arm: TAK-228 4 mgDose Expansion, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Weekly Dosing Arm: TAK-228 20 mgDose Escalation, Weekly Dosing Arm: TAK-228 30 mg
AUC∞: Area Under the Plasma Concentration-time Curve From 0 to Infinity for TAK-228 on Cycle 1 Day 1143.6467 ± 51.931204.3414 ± 36.134320.7879 ± 44.795192.1438 ± 41.8921636.7944 ± 49.9062010.7676 ± 53.638
SecondaryClinical Benefit Rate (CBR)

The CBR was defined as the percentage of participants with a best overall response (BOR) of complete response (CR), partial response (PR), or stable disease (SD). BOR was defined as the best response recorded after the first dose of study drug until subsequent therapy. As per Response Evaluation Criteria Solid Tumors (RECIST) version 1.1 guidelines, CR was defined as disappearance of all target lesions and non-target lesions, and normalization of tumor marker level. PR was defined as \>= 30% decrease in the sum of the longest diameter (LD) of target lesions, no progression in non-target lesion, and no new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression (PD). PD was defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.

Time frame:
Baseline Up to 1 Year 7 Months
Reported as:
Number · Percentage of participants
Clinical Benefit Rate (CBR)
Percentage of participantsDose Escalation, Daily Dosing Arm: TAK-228 2 mgDose Escalation, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Daily Dosing Arm: TAK-228 4 mgDose Expansion, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Weekly Dosing Arm: TAK-228 20 mgDose Escalation, Weekly Dosing Arm: TAK-228 30 mg
Clinical Benefit Rate (CBR)335057336767

Adverse events

Collected over TEAEs are AEs that started after the first dose of study drug and no more than 30 days after the last dose of study drug (up to Cycle 12 Day 58). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose Escalation, Daily Dosing Arm: TAK-228 2 mg0/3 (0%)0/3 (0%)3/3 (100%)
Dose Escalation, Daily Dosing Arm: TAK-228 3 mg0/6 (0%)2/6 (33.3%)6/6 (100%)
Dose Escalation, Daily Dosing Arm: TAK-228 4 mg0/7 (0%)3/7 (42.9%)7/7 (100%)
Dose Expansion, Daily Dosing Arm: TAK-228 3 mg0/6 (0%)1/6 (16.7%)6/6 (100%)
Dose Escalation, Weekly Dosing Arm: TAK-228 20 mg0/3 (0%)2/3 (66.7%)3/3 (100%)
Dose Escalation, Weekly Dosing Arm: TAK-228 30 mg0/3 (0%)1/3 (33.3%)3/3 (100%)
Most frequent serious events
Most frequent serious events
EventDose Escalation, Daily Dosing Arm: TAK-228 2 mgDose Escalation, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Daily Dosing Arm: TAK-228 4 mgDose Expansion, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Weekly Dosing Arm: TAK-228 20 mgDose Escalation, Weekly Dosing Arm: TAK-228 30 mg
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/30/60/70/61/30/3
Metastases to central nervous systemNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/30/60/70/60/31/3
EnteritisGastrointestinal disorders0/30/60/70/61/30/3
Cholangitis acuteHepatobiliary disorders0/30/60/70/61/30/3
Jaundice cholestaticHepatobiliary disorders0/30/60/71/60/30/3
Cerebrovascular accidentNervous system disorders0/31/60/70/60/30/3
Renal impairmentRenal and urinary disorders0/31/60/70/60/30/3
Genital HerpesInfections and infestations0/30/61/70/60/30/3
SepsisInfections and infestations0/30/61/70/60/30/3
Acute myocardial infarctionCardiac disorders0/30/61/70/60/30/3
Most frequent other events
Showing 10 of 90
Most frequent other events
EventDose Escalation, Daily Dosing Arm: TAK-228 2 mgDose Escalation, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Daily Dosing Arm: TAK-228 4 mgDose Expansion, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Weekly Dosing Arm: TAK-228 20 mgDose Escalation, Weekly Dosing Arm: TAK-228 30 mg
VomitingGastrointestinal disorders0/32/63/72/60/33/3
HyperglycaemiaMetabolism and nutrition disorders0/32/64/73/63/31/3
NauseaGastrointestinal disorders3/32/64/72/63/33/3
Blood alkaline phosphatase increasedInvestigations0/30/60/70/63/31/3
StomatitisGastrointestinal disorders0/35/64/75/61/31/3
Weight decreasedInvestigations1/33/63/70/62/31/3
Aspartate aminotransferase increasedInvestigations1/32/61/72/62/31/3
Alanine aminotransferase increasedInvestigations0/31/61/72/62/31/3
Decreased appetiteMetabolism and nutrition disorders2/31/64/74/62/31/3
Platelet count decreasedInvestigations0/31/62/73/60/31/3

Baseline characteristics

The safety analysis set included participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Dose Escalation, Daily Dosing Arm: TAK-228 2 mgDose Escalation, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Daily Dosing Arm: TAK-228 4 mgDose Expansion, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Weekly Dosing Arm: TAK-228 20 mgDose Escalation, Weekly Dosing Arm: TAK-228 30 mgTotal
Mean69.0 ± 5.2055.8 ± 12.5958.7 ± 10.3656.3 ± 11.557.0 ± 6.9354.0 ± 12.4958 ± 10.59
Sex: Female, Male
Sex: Female, Male(Participants)Dose Escalation, Daily Dosing Arm: TAK-228 2 mgDose Escalation, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Daily Dosing Arm: TAK-228 4 mgDose Expansion, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Weekly Dosing Arm: TAK-228 20 mgDose Escalation, Weekly Dosing Arm: TAK-228 30 mgTotal
Female12331212
Male24432116
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dose Escalation, Daily Dosing Arm: TAK-228 2 mgDose Escalation, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Daily Dosing Arm: TAK-228 4 mgDose Expansion, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Weekly Dosing Arm: TAK-228 20 mgDose Escalation, Weekly Dosing Arm: TAK-228 30 mgTotal
Hispanic or Latino0000000
Not Hispanic or Latino36763328
Unknown or Not Reported0000000
Region of Enrollment
Region of Enrollment(Participants)Dose Escalation, Daily Dosing Arm: TAK-228 2 mgDose Escalation, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Daily Dosing Arm: TAK-228 4 mgDose Expansion, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Weekly Dosing Arm: TAK-228 20 mgDose Escalation, Weekly Dosing Arm: TAK-228 30 mgTotal
Japan34333117
Taiwan, Province Of China0111003
Korea, Republic Of0132028
Height
Height(centimeter (cm))Dose Escalation, Daily Dosing Arm: TAK-228 2 mgDose Escalation, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Daily Dosing Arm: TAK-228 4 mgDose Expansion, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Weekly Dosing Arm: TAK-228 20 mgDose Escalation, Weekly Dosing Arm: TAK-228 30 mgTotal
Mean163.80 ± 10.000167.05 ± 10.135162.64 ± 5.839162.42 ± 10.619170.47 ± 12.003160.73 ± 8.923164.30 ± 8.96
Weight
Weight(kilogram (kg))Dose Escalation, Daily Dosing Arm: TAK-228 2 mgDose Escalation, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Daily Dosing Arm: TAK-228 4 mgDose Expansion, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Weekly Dosing Arm: TAK-228 20 mgDose Escalation, Weekly Dosing Arm: TAK-228 30 mgTotal
Mean63.33 ± 11.20164.87 ± 13.95862.09 ± 11.98261.87 ± 17.49061.43 ± 6.30063.43 ± 10.00162.84 ± 12.08
Smoking Classification
Smoking Classification(Participants)Dose Escalation, Daily Dosing Arm: TAK-228 2 mgDose Escalation, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Daily Dosing Arm: TAK-228 4 mgDose Expansion, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Weekly Dosing Arm: TAK-228 20 mgDose Escalation, Weekly Dosing Arm: TAK-228 30 mgTotal
Never Smoked36662326
Moderate Smoker (6-20 Cigarettes/ day)0010001
Unknown0000101
Asian Sub-Category
Asian Sub-Category(Participants)Dose Escalation, Daily Dosing Arm: TAK-228 2 mgDose Escalation, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Daily Dosing Arm: TAK-228 4 mgDose Expansion, Daily Dosing Arm: TAK-228 3 mgDose Escalation, Weekly Dosing Arm: TAK-228 20 mgDose Escalation, Weekly Dosing Arm: TAK-228 30 mgTotal
Japanese34333117
Korean0132028
Chinese0111003
08

Study locations

4 sites
  • National Cancer Center Hospital East
    Kashiwa-shi, Chiba-Ken 277-8577, Japan
  • National Cancer Center Hospital
    Chuo-ku, Tokyo-To 104-0045, Japan
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
  • National Taiwan-University Hospital
    Taipei, 100, Taiwan
09

References and documents

Publications

  • Shimizu T, Kuboki Y, Lin CC, Yonemori K, Yanai T, Faller DV, Dobler L, Gupta N, Sedarati F, Kim KP. A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies. Target Oncol. 2022 Jan;17(1):15-24. doi: 10.1007/s11523-021-00855-w. Epub 2021 Nov 29. Erratum In: Target Oncol. 2022 May;17(3):377. doi: 10.1007/s11523-022-00881-2. PubMed 34843044 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2018 to primary completion in Aug 2019, 19 months.

Results were first posted in Sep 2020, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2017
First posted
Dec 12, 2017
StartActual
Jan 17, 2018
Primary completionActual
Aug 28, 2019
CompletionActual
Aug 28, 2019
Results first posted
Sep 9, 2020
Last update
Feb 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03370302
Responsible party
Sponsor
First posted
Dec 12, 2017
Start date
Jan 17, 2018
Primary completion
Aug 28, 2019
Completion
Aug 28, 2019
Results posted
Sep 9, 2020
Last update
Feb 8, 2023

Study contacts

Medical Director
study director · Millennium Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sapanisertib

Start the discussion